查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1762522

反义寡核苷酸市场：产业趋势及全球预测 - 依反义分子类型、反义寡核苷酸生成类型、标靶适应症、给药途径、治疗类型和地区

Antisense Oligonucleotides Market: Industry Trends and Global Forecasts - Distribution by Type of Antisense Molecule, Type of ASO Generation, Target Disease Indication, Route of Administration, Type of Therapy, and Geography
出版日期: | 出版商: Roots Analysis | 英文 252 Pages | 商品交期: 最快1-2个工作天内

价格

反义寡核苷酸市场：概览

今年反义寡核苷酸市场规模估计为 25亿美元，预计在预测期内的年复合成长率为 15%。

本市场细分依据以下参数划分市场规模与机会：

反义分子类型

  • DNA分子
  • RNA分子

反义寡核苷酸（ASO）的代数

  • 第一代产品
  • 第二代产品
  • 第三代产品

目标适应症

  • 肌萎缩侧索硬化症
  • 杜氏肌肉营养不良症
  • 家族性乳糜微粒血症综合症
  • 家族性局部脂质营养不良
  • 遗传性转甲状腺素蛋白（hATTR）淀粉样变性
  • 亨丁顿舞蹈症
  • 莱伯氏先天性黑曚症
  • 脊髓性肌肉萎缩症

给药途径

  • 鞘内给药
  • 静脉给药
  • 玻璃体内治疗
  • 皮下治疗
  • Intraorifice治疗

治疗类型

  • 合併治疗
  • 单药治疗

地区

  • 北美
  • 欧洲
  • 亚太地区
  • 世界其他地区

反义寡核苷酸市场：成长与趋势

寡核苷酸是由15-20个核苷酸残基组成的短的单股DNA或RNA分子。在现代生物製药中，这些寡核苷酸的应用非常广泛，包括但不限于基因检测、基础生物分子研究和法医分析。反义寡核苷酸是一种功能多样的寡核苷酸，是短链单股RNA/DNA分子，能够特异性结合标靶mRNA，并且能够透过多种机制改变蛋白质表现。

Antisense Oligonucleus Market-IMG1

反义疗法被认为是最有前景的药物之一，它可以抑制蛋白质生成并抑制人类基因组中特定目标基因的功能。目前，这种机制是许多处于临床试验不同阶段的治疗药物的基础，这些药物用于治疗各种疾病，包括肿瘤、遗传、肝臟、呼吸系统和传染病。事实上，近年来，寡核苷酸药物的开发者也在研究寡核苷酸干预措施对抗冠状病毒（COVID-19）的适用性。鑑于反义寡核苷酸市场的创新和发展速度，预计反义寡核苷酸将成为未来的主要治疗途径。

反义寡核苷酸市场：关键洞察

本报告分析了反义寡核苷酸市场的现状，并指出了潜在的成长机会。报告的主要调查结果包括：

  • 目前，全球约有 30 家公司研究治疗各种适应症的药物，以评估反义寡核苷酸的潜在治疗效果。
  • 目前有超过 170 种处于不同开发阶段的候选药物研发中，这些药物被评估为单药治疗或与其他治疗药物合併使用。
  • 大多数已核准的治疗药物和后期候选药物都目的是治疗遗传、神经系统和肿瘤疾病。
  • 鑑于反义寡核苷酸的益处，这些干预措施主要作为单药疗法进行评估。目前研究作为单药疗法的后期药物包括Tofersen和Pelacarsen。
  • 已有超过18,000名患者入组临床试验，评估近70种基于反义寡核苷酸的候选疗法。
Antisense Oligonucleus Market-IMG2
  • 大多数反义寡核苷酸疗法设计为皮下给药，但患者也可以使用各种给药系统自行给药。
  • 一些组织为该领域的研究活动提供资金支持。目前，重点主要放在研究治疗神经系统疾病的药物。
  • 过去几年，美国授予该领域的利害关係人资助金额稳定成长，其中超过70%的金额用于研究计画。
  • NIH的各个管理机构都参与了该领域，其中NINDS、NHLBI和NCI尤为突出。
  • 各利害关係人在不同应用领域建立的合作关係数量也反映了人们对该领域日益成长的兴趣。
  • 目前有近20个分子处于后期开发阶段，各公司之间的合作主要是为了产品开发和商业化。
  • 过去，老牌企业和新进者都建立了策略伙伴关係，这些协议主要针对遗传和神经系统疾病。
  • 就上市药物和后期药物的销售收入而言，未来的机会预计将在不同的疾病领域、分子类型和主要地理区域呈现高度多样化。
反义寡核苷酸市场-IMG3
  • 未来十年，该市场可能会持续稳定成长，不同世代、不同给药途径和不同治疗类型的市场机会也将更加多样化。

反义寡核苷酸市场参与者范例

  • Antisense Therapeutics
  • Biogen
  • Bio-Path Holdings
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
  • Wave Life Sciences

目录

第1章 简介

第2章 执行摘要

第3章 简介

  • 章节概述
  • 寡核苷酸及相关药物概述
    • 寡核苷酸的类型
  • 寡核苷酸治疗学
    • RNA干扰治疗学
    • 反义寡核苷酸治疗学
  • 未来展望

第4章 反义寡核苷酸治疗学：市场格局

  • 章节概述
  • 反义寡核苷酸治疗学：研发管线回顾
    • 依反义分子类型分析
    • 依ASO世代分析
    • 依开发阶段分析
    • 依目标基因分析
    • 依标靶适应症分析
    • 依治疗领域分析
    • 依给药途径分析
    • 依治疗方案分析
  • 反义寡核苷酸治疗学：开发商名单
    • 依成立年份分析
    • 依公司规模分析

第4章 依总部位置分析

第5章 公司简介

  • 章节概述
  • Antisense Therapeutics
  • Biogen
  • Bio-Path Holdings
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
  • Wave Life Sciences

第6章 临床试验分析

  • 章节概述
  • 研究范围与研究方法
  • 反义寡核苷酸疗法：临床试验分析

第7章 学术资助分析

  • 章节概述
  • 范围与方法
  • 反义寡核苷酸疗法：学术资助分析

第8章 合作伙伴关係与合作

  • 章节概述
  • 合作模式
  • 反义寡核苷酸疗法：合作关係与合作概览

第9章 市场预测与机会分析

  • 章节概述
  • 预测研究方法与关键假设
  • 2035年全球反义寡核苷酸疗法市场
  • 2035年全球反义寡核苷酸疗法市场：单一产品销售预测
  • 2035年全球反义寡核苷酸疗法市场：依反义分子类型
  • 2035年全球反义寡核苷酸治疗市场：依ASO代数
  • 2035年全球反义寡核苷酸治疗市场：依标靶适应症
  • 2035年全球反义寡核苷酸治疗市场：依给药途径
  • 2035年全球反义寡核苷酸治疗市场：依治疗类型
  • 2035年全球反义寡核苷酸治疗市场：依地区

第10章 案例研究：寡核苷酸製造商和纯化服务

  • 章节概述
  • 专门用于研究和诊断应用的寡核苷酸製造商列表
  • 专门用于治疗应用的寡核苷酸製造商列表

第11章 结论

第12 附录1 表格资料

第13章 附录2 公司与组织清单

Product Code: RA100243

ANTISENSE OLIGONUCLEOTIDES MARKET: OVERVIEW

As per Roots Analysis, the global antisense oligonucleotides market valued at USD 2.5 billion in the current year is anticipated to grow at a lucrative CAGR of 15% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Antisense Molecule

  • DNA Molecules
  • RNA Molecules

Type of ASO Generation

  • First-Generation Products
  • Second-Generation Products
  • Third-Generation Products

Target Disease Indication

  • Amyotrophic Lateral Sclerosis
  • Duchenne Muscular Dystrophy
  • Familial Chylomicronemia Syndrome
  • Familial Partial Lipodystrophy
  • Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
  • Huntington's Disease
  • Leber's Congenital Amaurosis
  • Spinal Muscular Atrophy

Route of Administration

  • Intrathecal Therapies
  • Intravenous Therapies
  • Intravitreal Therapies
  • Subcutaneous Therapies
  • Intraorifice Therapies

Type of Therapy

  • Combination Therapies
  • Monotherapies

Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

ANTISENSE OLIGONUCLEOTIDES MARKET: GROWTH AND TRENDS

Oligonucleotides are short single stranded DNA or RNA molecules, that comprise 15-20 nucleotide residues. In modern biopharmaceuticals, the applications of these oligonucleotides are vast, including (but not limited to) genetic testing, fundamental biomolecular research, and forensic analysis. Antisense oligonucleotides, a diverse class of oligonucleotides are short, single-stranded RNA / DNA molecules specifically binding to the target mRNA and have the ability to modify protein expression through a variety of mechanisms.

Antisense Oligonucleotides Market - IMG1

Antisense therapeutics are considered to be one of the most promising agents for impairing protein production and blocking the function of the specific target gene of interest in the human genome. Presently, this mechanism forms the basis for many therapeutics being investigated in different stages of clinical trials for treatment of a variety of disorders, including oncological disorders, genetic diseases, hepatic diseases, respiratory disorders and infectious diseases. In fact, in the recent past, the oligonucleotide drug developers had also investigated the relevance of these interventions against the Coronavirus (COVID-19). Given the pace of innovation and developments in the antisense oligonucleotides market, we can expect antisense oligonucleotides to become a major therapeutic modality in the foreseen future.

ANTISENSE OLIGONUCLEOTIDES MARKET: KEY INSIGHTS

The report delves into the current state of the antisense oligonucleotides market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Around 30 players from are presently engaged in evaluating the potential therapeutic benefits of antisense oligonucleotides for the treatment of a wide range of disease indications, worldwide.
  • The pipeline features 170+ candidate therapies in different stages of development, being evaluated either as monotherapies or in combination with other interventions; most of these products are administered parenterally.
  • Majority of the approved therapies and late-stage candidates are intended for the treatment of genetic disorders, neurological disorders and oncological disorders.
  • Given the advantages of antisense oligonucleotides, these interventions are primarily evaluated as monotherapy. Late-stage drugs being investigated as monotherapy include Tofersen and Pelacarsen.
  • Over 18,000 patients have been enrolled in clinical trial sites evaluating close to 70 antisense oligonucleotide-based therapy candidates.
Antisense Oligonucleotides Market - IMG2
  • Majority of the antisense oligonucleotide therapeutics are designed for subcutaneous administration; these can be self-administered by the patients using different drug delivery systems.
  • Several organizations have extended financial support to aid research efforts in this domain; currently, the focus, in terms of funds disbursed, is primarily in support of investigations of drugs for treating neurological conditions.
  • The number of grants awarded to stakeholders in this domain (in the US) has continuously increased in the past few years; more than 70% of the total amount was awarded for research projects.
  • The field has witnessed the involvement of various administering institutes of the NIH; of all the institutes, participation of the NINDS, NHLBI, and NCI has been relatively more prominent.
  • The rising interest in this field is reflected in the number of partnerships inked by the various stakeholders across different application areas.
  • Given that nearly 20 molecules are in the late stages of development, companies have primarily collaborated for product development and commercialization purposes.
  • Both established players and the new entrants have forged strategic partnerships in the recent past; these deals have primarily been inked for genetic and neurological disorders.
  • The future opportunity, in terms of revenues from the sales of marketed and late-stage therapies, is anticipated to be well distributed across different disease areas, types of molecules and key geographical regions.
Antisense Oligonucleotides Market - IMG3
  • The market is likely to witness steady growth over the coming decade; the opportunity will be dispersed across different generations, routes of administration and various types of therapies.

Example Players in the Antisense Oligonucleotides Market

  • Antisense Therapeutics
  • Biogen
  • Bio-Path Holdings
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
  • Wave Life Sciences

ANTISENSE OLIGONUCLEOTIDES MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global antisense oligonucleotides market, focusing on key market segments, including [A] type of antisense molecule, [B] type of ASO generation, [C] target disease indication, [D] route of administration, [E] type of therapy and [F] geography.
  • Market Landscape: A comprehensive evaluation of antisense oligonucleotide therapeutics, based on several relevant parameters, such as [A] type of antisense molecule, [B] ASO generation, [C] phase of development of lead candidates, [D] target genes, [E] target disease indications, [F] target therapeutic areas, [G] route of administration and [H] type of therapy. Additionally, a comprehensive evaluation of drug developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
  • Company Profiles: In-depth profiles of antisense oligonucleotide therapeutic developers, focusing on [A] overview of the company, [B] financial information (if available), [C] product portfolio and [D] recent developments and an informed future outlook.
  • Clinical Trial Analysis: An insightful analysis of clinical trials related to antisense oligonucleotide therapeutics, based on several parameters, such as [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] enrolled patient population, [E] study design, leading industry sponsors / collaborators (in terms of number of trials conducted), [F] trial focus, [G] target therapeutic area and [H] target genes.
  • Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes for antisense oligonucleotide therapeutic projects, based on various relevant parameters, such as [A] year of grant award, [B] amount awarded, [C] administering institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] type of recipient organizations and [J] focus area. Additionally, a comprehensive assessment of grants focusing on, [A] geographical distribution of recipient organizations, [B] popular therapeutic areas, [C] popular funding institute centers, [D] prominent program officers and [E] popular recipient organizations.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the antisense oligonucleotide market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] most active players (in terms of number of partnerships signed) and [D] regional analysis.
  • Case Study: A detailed discussion on the oligonucleotide CMOs and purification service providers, highlighting information on the [A] year of establishment, [B] company size, [C] scale of operation, [D] location of headquarters and [E] type of purification method used.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview on Oligonucleotides and Affiliated Medical Products
    • 3.2.1. Types of Oligonucleotides
      • 3.2.1.1. Antisense Oligonucleotides (ASOs)
      • 3.2.1.2. Aptamers
      • 3.2.1.3. miRNA
      • 3.2.1.4. shRNA
      • 3.2.1.5. siRNA
      • 3.2.1.6. Other Oligonucleotides
  • 3.3. Oligonucleotide Therapeutics
    • 3.3.1. RNA-Interference Therapeutics
      • 3.3.1.1. Components of RNA-Interference Therapeutics
      • 3.3.1.2. Mechanism of RNA-Interference Therapeutics
    • 3.3.2. Antisense Oligonucleotide Therapeutics
      • 3.3.2.1. Mechanism of Antisense Oligonucleotide Therapeutics
      • 3.3.2.2. Types of Antisense Oligonucleotide Therapeutics
  • 3.4. Future Perspectives

4. ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Antisense Oligonucleotide Therapeutics: Pipeline Review
    • 4.2.1. Analysis by Type of Antisense Molecule
    • 4.2.2. Analysis by ASO Generation
    • 4.2.3. Analysis by Phase of Development
    • 4.2.4. Analysis by Target Genes
    • 4.2.5. Analysis by Target Indications
    • 4.2.6. Analysis by Therapeutic Areas
    • 4.2.7. Analysis by Route of Administration
    • 4.2.8. Analysis by Type of Therapy
  • 4.3. Antisense Oligonucleotide Therapeutics: List of Developers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size

4. 3.3. Analysis by Location of Headquarters

  • 4.4. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Antisense Therapeutics
    • 5.2.1. Company Overview
    • 5.2.2. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.2.3. Recent Developments and Future Outlook
  • 5.3. Biogen
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. Bio-Path Holdings
    • 5.4.1. Company Overview
    • 5.4.2. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.4.3. Recent Developments and Future Outlook
  • 5.5. Ionis Pharmaceuticals
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. ProQR Therapeutics
    • 5.6.1. Company Overview
    • 5.6.2. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.6.3. Recent Developments and Future Outlook
  • 5.7. Sarepta Therapeutics
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Sterna Biologicals
    • 5.8.1. Company Overview
    • 5.8.2. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.8.3. Recent Developments and Future Outlook
  • 5.9. Wave Life Sciences
    • 5.9.1. Company Overview
    • 5.9.2. Financial Information
    • 5.9.3. Antisense Oligonucleotide Therapeutics Portfolio
    • 5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Antisense Oligonucleotide Therapeutics: Clinical Trial Analysis
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Trial Phase
    • 6.3.3. Analysis by Trial Recruitment Status
    • 6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
    • 6.3.5. Analysis by Study Design
    • 6.3.6. Analysis by Type of Sponsor / Collaborator
    • 6.3.7. Leading Players: Analysis by Number of Registered Trials
    • 6.3.8. Word Cloud: Key Focus Areas
    • 6.3.9. Analysis by Target Therapeutic Area
    • 6.3.10. Analysis by Trial Registration Year and Target Gene
    • 6.3.11. Popular Indications: Analysis by Number of Registered Trials
    • 6.3.12. Popular Interventions: Analysis by Number of Registered Trials
    • 6.3.13. Geographical Analysis by Number of Registered Trials
    • 6.3.14. Geographical Analysis by Number of Patients Enrolled

7. ACADEMIC GRANTS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Antisense Oligonucleotide Therapeutics: Analysis of Academic Grants
    • 7.3.1. Analysis by Year of Grant Award
    • 7.3.2. Analysis by Amount Awarded
    • 7.3.3. Analysis by Administering Institute Center
    • 7.3.4. Analysis by Support Period
    • 7.3.5. Analysis by Administering Institute Center and Support Period
    • 7.3.6. Analysis by Type of Grant Application
    • 7.3.7. Analysis by Purpose of Grant Award
    • 7.3.8. Analysis by Activity Code
    • 7.3.9. Analysis by Study Section Involved
    • 7.3.10. Analysis by Type of Recipient Organization
    • 7.3.11. Word Cloud Analysis: Emerging Focus Areas
    • 7.3.12. Geographical Distribution of Recipient Organizations
    • 7.3.13. Popular Therapeutic Areas: Analysis by Number of Grants
    • 7.3.14. Popular NIH Departments: Analysis by Number of Grants
    • 7.3.15. Prominent Program Officers: Analysis by Number of Grants
    • 7.3.16. Popular Recipient Organizations: Analysis by Number of Grants

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Antisense Oligonucleotide Therapeutics: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Type of Partnership and Generation of Antisense Molecule Involved
    • 8.3.4. Analysis by Type of Partnership and Target Therapeutic Area
    • 8.3.5. Analysis by Year of Partnership and Type of Partner
    • 8.3.6. Analysis by Type of Partnership and Type of Partner
    • 8.3.7. Most Active Players: Analysis by Number of Partnerships
    • 8.3.8. Regional Analysis
      • 8.3.8.1. Intercontinental and Intracontinental Agreements

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology and Key Assumptions
  • 9.3. Global Antisense Oligonucleotide Therapeutics Market, Till 2035
  • 9.4. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Individual Product Sales Forecasts
    • 9.4.1. Alicaforsen (Atlantic Healthcare)
      • 9.4.1.1. Target Patient Population
      • 9.4.1.2. Sales Forecast
    • 9.4.2. Eteplirsen (Sarepta Therapeutics)
      • 9.4.2.1. Target Patient Population
      • 9.4.2.2. Sales Forecast
    • 9.4.3. Golodirsen (Sarepta Therapeutics)
      • 9.4.3.1. Target Patient Population
      • 9.4.3.2. Sales Forecast
    • 9.4.4. Inotersen (Ionis Pharmaceuticals)
      • 9.4.4.1. Target Patient Population
      • 9.4.4.2. Sales Forecast
    • 9.4.5. Sepofarsen (ProQR Therapeutics)
      • 9.4.5.1. Target Patient Population
      • 9.4.5.2. Sales Forecast
    • 9.4.6. Tofersen (Biogen)
      • 9.4.6.1. Target Patient Population
      • 9.4.6.2. Sales Forecast
    • 9.4.7. Tominersen (Roche)
      • 9.4.7.1. Target Patient Population
      • 9.4.7.2. Sales Forecast
    • 9.4.8. Viltolarsen (Nippon Shinyaku)
      • 9.4.8.1. Target Patient Population
      • 9.4.8.2. Sales Forecast
    • 9.4.9. Volanesorsen (Ionis Pharmaceuticals)
      • 9.4.9.1. Target Patient Population
      • 9.4.9.2. Sales Forecast
  • 9.5. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Antisense Molecule
    • 9.5.1. Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, Till 2035
    • 9.5.2. Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, Till 2035
  • 9.6. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by ASO Generation
    • 9.6.1. Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, Till 2035
    • 9.6.2. Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, Till 2035
    • 9.6.3. Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, Till 2035
  • 9.7. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Target Disease Indication
    • 9.7.1. Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, Till 2035
    • 9.7.2. Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, Till 2035
    • 9.7.3. Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, Till 2035
    • 9.7.4. Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, Till 2035
    • 9.7.5. Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, Till 2035
    • 9.7.6. Global Antisense Oligonucleotide Therapeutics Market for Huntington's Disease, Till 2035
    • 9.7.7. Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, Till 2035
    • 9.7.8. Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, Till 2035
    • 9.7.9. Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, Till 2035
  • 9.8. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Route of Administration
    • 9.8.1. Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, Till 2035
    • 9.8.2. Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, Till 2035
    • 9.8.3. Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, Till 2035
    • 9.8.4. Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, Till 2035
    • 9.8.5. Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, Till 2035
  • 9.9. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Therapy
    • 9.9.1. Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies Till 2035
    • 9.9.2. Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, Till 2035
  • 9.10. Global Antisense Oligonucleotide Market, Till 2035: Geographical Distribution
    • 9.10.1. Antisense Oligonucleotide Market in the US, Till 2035
    • 9.10.2. Antisense Oligonucleotide Market in Canada, Till 2035
    • 9.10.3. Antisense Oligonucleotide Market in the UK, Till 2035
    • 9.10.4. Antisense Oligonucleotide Market in Germany, Till 2035
    • 9.10.5. Antisense Oligonucleotide Market in France, Till 2035
    • 9.10.6. Antisense Oligonucleotide Market in Italy, Till 2035
    • 9.10.7. Antisense Oligonucleotide Market in Spain, Till 2035
    • 9.10.8. Antisense Oligonucleotide Market in Australia, Till 2035
    • 9.10.9. Antisense Oligonucleotide Market in Japan, Till 2035
    • 9.10.10. Antisense Oligonucleotide Market in Korea, Till 2035
    • 9.10.11. Antisense Oligonucleotide Market in Brazil, Till 2035
    • 9.10.12. Antisense Oligonucleotide Market in Israel, Till 2035

10. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERS AND PURIFICATION SERVICES

  • 10.1. Chapter Overview
  • 10.2. List of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
    • 10.2.1. Analysis by Year of Establishment
    • 10.2.2. Analysis by Company Size
    • 10.2.3. Analysis by Scale of Operation
    • 10.2.4. Analysis by Location of Headquarters
    • 10.2.5. Analysis by Type of Purification Method Used
  • 10.3. List of Oligonucleotide Manufacturers Focused on Therapeutic Applications
    • 10.3.1. Analysis by Year of Establishment
    • 10.3.2. Analysis by Company Size
    • 10.3.3. Analysis by Scale of Operation
    • 10.3.4. Analysis by Location of Headquarters
    • 10.3.5. Analysis by Type of Purification Method Used

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 Antisense Oligonucleotide Therapeutics: List of Drugs
  • Table 4.2 Antisense Oligonucleotide Therapeutics: List of Developers
  • Table 5.1 Antisense Oligonucleotide Therapeutics: List of Companies Profiled
  • Table 5.2 Antisense Therapeutics: Company Snapshot
  • Table 5.3 Drug Profile: ATL1102
  • Table 5.4 Drug Profile: ATL1103
  • Table 5.5 Antisense Therapeutics: Recent Developments and Future Outlook
  • Table 5.6 Biogen: Company Snapshot
  • Table 5.7 Drug Profile: Tofersen
  • Table 5.8 Drug Profile: ION541
  • Table 5.9 Biogen: Recent Developments and Future Outlook
  • Table 5.10 Bio-Path Holdings: Company Snapshot
  • Table 5.11 Drug Profile: Prexigebersen
  • Table 5.12 Drug Profile: BP1002
  • Table 5.13 Drug Profile: BP1003
  • Table 5.14 Bio-Path Holdings: Recent Developments and Future Outlook
  • Table 5.15 Ionis Pharmaceuticals: Company Snapshot
  • Table 5.16 Drug Profile: Spinraza(R)
  • Table 5.17 Drug Profile: Tegsedi(R)
  • Table 5.18 Drug Profile: Waylivra(R)
  • Table 5.19 Drug Profile: AKCEA-APOCIII-LRx
  • Table 5.20 Drug Profile: IONIS-PKK-LRx
  • Table 5.21 Drug Profile: IONIS-PKK-Rx
  • Table 5.22 Drug Profile: IONIS-ENAC-2.5Rx
  • Table 5.23 Drug Profile: IONIS-FB-LRx
  • Table 5.24 Drug Profile: IONIS-AGT-LRx
  • Table 5.25 Drug Profile: AKCEA-TTR-LRx
  • Table 5.26 Drug Profile: IONIS-GHR-LRx
  • Table 5.27 Drug Profile: ION253
  • Table 5.28 Drug Profile: IONIS-TMPRSS6-LRx
  • Table 5.29 Drug Profile: ION736
  • Table 5.30 Drug Profile: IONIS-AR-2.5Rx
  • Table 5.31 Drug Profile: ION224
  • Table 5.32 Drug Profile: ISIS-FGFR4RX
  • Table 5.33 Drug Profile: ISIS-GCCRRx
  • Table 5.34 Drug Profile: IONIS-GCGRRx
  • Table 5.35 Drug Profile: IONIS-HBV-LRx
  • Table 5.36 Drug Profile: ION251
  • Table 5.37 Drug Profile: ION 449
  • Table 5.38 Drug Profile: BIIB078
  • Table 5.39 Drug Profile: BIIB094
  • Table 5.40 Drug Profile: BIIB101
  • Table 5.41 Drug Profile: ISIS-EIF4ERx
  • Table 5.42 Drug Profile: BIIB080
  • Table 5.43 Drug Profile: ION663
  • Table 5.44 Drug Profile: ION674
  • Table 5.45 Drug Profile: ION537
  • Table 5.46 Drug Profile: ION929
  • Table 5.47 Drug Profile: ION363
  • Table 5.48 Drug Profile: ION373
  • Table 5.49 Drug Profile: ION283
  • Table 5.50 Drug Profile: ION260
  • Table 5.51 Drug Profile: ION581
  • Table 5.52 Drug Profile: ION716
  • Table 5.53 Drug Profile: ION904
  • Table 5.54 Drug Profile: ION547
  • Table 5.55 Ionis Pharmaceuticals: Recent Developments and Future Outlook
  • Table 5.56 ProQR Therapeutics: Company Snapshot
  • Table 5.57 Drug Profile: Sepofarsen
  • Table 5.58 Drug Profile: QR-421a
  • Table 5.59 Drug Profile: QR-1123
  • Table 5.60 Drug Profile: QR-411
  • Table 5.61 Drug Profile: QR-504a
  • Table 5.62 Drug Profile: QRX-704
  • Table 5.63 Drug Profile: QR-1011
  • Table 5.64 Drug Profile: QRX-461
  • Table 5.65 Drug Profile: QRX-136
  • Table 5.66 Drug Profile: QRX-1204
  • Table 5.67 ProQR Therapeutics: Recent Developments and Future Outlook
  • Table 5.68 Sarepta Therapeutics: Company Snapshot
  • Table 5.69 Drug Profile: Exondys 51
  • Table 5.70 Drug Profile: Vyondys 53
  • Table 5.71 Drug Profile: Amondys 45
  • Table 5.72 Drug Profile: SRP-5051
  • Table 5.73 Drug Profile: Exon 52
  • Table 5.74 Drug Profile: Exon 43
  • Table 5.75 Drug Profile: Exon 44
  • Table 5.76 Drug Profile: Exon 50
  • Table 5.77 Drug Profile: Exon 55
  • Table 5.78 Drug Profile: SRP-5052
  • Table 5.79 Drug Profile: SRP-5053
  • Table 5.80 Drug Profile: SRP-5044
  • Table 5.81 Drug Profile: SRP-5045
  • Table 5.82 Drug Profile: SRP-5050
  • Table 5.83 Sarepta Therapeutics: Recent Developments and Future Outlook
  • Table 5.84 Sterna Biologicals: Company Snapshot
  • Table 5.85 Drug Profile: SB010
  • Table 5.86 Drug Profile: SB011
  • Table 5.87 Drug Profile: SB012
  • Table 5.88 Sterna Biologicals: Recent Developments and Future Outlook
  • Table 5.89 Wave Life Sciences: Company Snapshot
  • Table 5.90 Drug Profile: WVE-120102
  • Table 5.91 Drug Profile: Suvodirsen
  • Table 5.92 Drug Profile: WVE-004
  • Table 5.93 Drug Profile: WVE-003
  • Table 5.94 Drug Profile: WVE-N531
  • Table 5.95 Drug Profile: Undisclosed Drug 1
  • Table 5.96 Drug Profile: Undisclosed Drug 2
  • Table 5.97 Drug Profile: Undisclosed Drug 3
  • Table 5.98 Drug Profile: Undisclosed Drug 4
  • Table 5.99 Drug Profile: Undisclosed Drug 5
  • Table 5.100 Drug Profile: Undisclosed Drug 6
  • Table 5.101 Wave Life Sciences: Recent Developments and Future Outlook
  • Table 8.1 Antisense Oligonucleotide Therapeutics: List of Partnerships and Collaborations
  • Table 9.1 Antisense Oligonucleotide Therapeutics: Summary of the Competitive Insights
  • Table 10.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
  • Table 10.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
  • Table 12.1 Antisense Oligonucleotide Therapeutics: Distribution by Type of Antisense Molecule
  • Table 12.2 Antisense Oligonucleotide Therapeutics: Distribution by ASO Generation
  • Table 12.3 Antisense Oligonucleotide Therapeutics: Distribution by Phase of Development
  • Table 12.4 Antisense Oligonucleotide Therapeutics: Distribution by Target Genes
  • Table 12.5 Antisense Oligonucleotide Therapeutics: Distribution by Target Indications
  • Table 12.6 Antisense Oligonucleotide Therapeutics: Distribution by Therapeutic Areas
  • Table 12.7 Antisense Oligonucleotide Therapeutics: Distribution by Route of Administration
  • Table 12.8 Antisense Oligonucleotide Therapeutics: Distribution by Type of Therapy
  • Table 12.9 Antisense Oligonucleotide Therapeutic Developers: Distribution by Year of Establishment
  • Table 12.10 Antisense Oligonucleotide Therapeutic Developers: Distribution by Company Size
  • Table 12.11 Antisense Oligonucleotide Therapeutic Developers: Distribution by Location of Headquarters
  • Table 12.12 Biogen: Annual Revenues, Since 2015 (USD Million)
  • Table 12.13 Ionis Pharmaceuticals: Annual Revenues, Since 2015 (USD Million)
  • Table 12.14 Sarepta Therapeutics: Annual Revenues, Since 2015 (USD Million)
  • Table 12.15 Wave Life Sciences: Annual Revenues, Since 2015 (USD Million)
  • Table 12.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
  • Table 12.17 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 12.18 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table 12.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Table 12.20 Clinical Trial Analysis: Distribution by Study Design
  • Table 12.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 12.22 Leading Players: Distribution by Number of Registered Trials
  • Table 12.23 Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Table 12.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
  • Table 12.25 Popular Indications: Distribution by Number of Registered Trials
  • Table 12.26 Popular Interventions: Distribution by Number of Registered Trials
  • Table 12.27 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Table 12.28 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Table 12.29 Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2017
  • Table 12.30 Grant Analysis: Cumulative Distribution by Amount Awarded, Since 2017 (USD Million)
  • Table 12.31 Grant Analysis: Distribution by Administering Institute Center
  • Table 12.32 Grant Analysis: Distribution by Support Period
  • Table 12.33 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Table 12.34 Grant Analysis: Distribution by Type of Grant Application
  • Table 12.35 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 12.36 Grant Analysis: Distribution by Activity Code
  • Table 12.37 Grant Analysis: Distribution by Study Section Involved
  • Table 12.38 Grant Analysis: Distribution by Type of Recipient Organization
  • Table 12.39 Grant Analysis: Geographical Distribution of Recipient Organizations
  • Table 12.40 Popular Therapeutic Areas: Distribution by Number of Grants
  • Table 12.41 Popular NIH Departments: Distribution by Number of Grants
  • Table 12.42 Prominent Program Officers: Distribution by Number of Grants
  • Table 12.43 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 12.44 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
  • Table 12.45 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.46 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Antisense Molecule Involved
  • Table 12.47 Partnerships and Collaborations: Distribution by Type of Partnership and Target Therapeutic Area
  • Table 12.48 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 12.49 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 12.50 Most Active Players: Distribution by Number of Partnerships
  • Table 12.51 Partnerships and Collaborations: Regional Distribution
  • Table 12.52 Global Antisense Oligonucleotide Therapeutics Market, Till 2035 (USD Million)
  • Table 12.53 Alicaforsen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.54 Eteplirsen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.55 Golodirsen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.56 Inotersen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.57 Sepofarsen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.58 Tofersen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.59 Tominersen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.60 Viltolarsen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.61 Volanesorsen: Sales Forecast, Till 2035 (USD Million)
  • Table 12.62 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Antisense Molecule (USD Million)
  • Table 12.63 Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, Till 2035 (USD Million)
  • Table 12.64 Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, Till 2035 (USD Million)
  • Table 12.65 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by ASO Generation (USD Million)
  • Table 12.66 Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, Till 2035 (USD Million)
  • Table 12.67 Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, Till 2035 (USD Million)
  • Table 12.68 Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, Till 2035 (USD Million)
  • Table 12.69 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Target Disease Indication (USD Million)
  • Table 12.70 Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, Till 2035 (USD Million)
  • Table 12.71 Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, Till 2035 (USD Million)
  • Table 12.72 Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, Till 2035 (USD Million)
  • Table 12.73 Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, Till 2035 (USD Million)
  • Table 12.74 Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, Till 2035 (USD Million)
  • Table 12.75 Global Antisense Oligonucleotide Therapeutics Market for Huntington's Disease, Till 2035 (USD Million)
  • Table 12.76 Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, Till 2035 (USD Million)
  • Table 12.77 Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, Till 2035 (USD Million)
  • Table 12.78 Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, Till 2035 (USD Million)
  • Table 12.79 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Route of Administration (USD Million)
  • Table 12.80 Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, Till 2035 (USD Million)
  • Table 12.81 Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, Till 2035 (USD Million)
  • Table 12.82 Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, Till 2035 (USD Million)
  • Table 12.83 Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, Till 2035 (USD Million)
  • Table 12.84 Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, Till 2035 (USD Million)
  • Table 12.85 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Therapy (USD Million)
  • Table 12.86 Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies Till 2035 (USD Million)
  • Table 12.87 Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, Till 2035 (USD Million)
  • Table 12.88 Global Antisense Oligonucleotide Market, Till 2035: Distribution by Geography (USD Million)
  • Table 12.89 Antisense Oligonucleotide Market in the US, Till 2035 (USD Million)
  • Table 12.90 Antisense Oligonucleotide Market in Canada, Till 2035 (USD Million)
  • Table 12.91 Antisense Oligonucleotide Market in the UK, Till 2035 (USD Million)
  • Table 12.92 Antisense Oligonucleotide Market in Germany, Till 2035 (USD Million)
  • Table 12.93 Antisense Oligonucleotide Market in France, Till 2035 (USD Million)
  • Table 12.94 Antisense Oligonucleotide Market in Italy, Till 2035 (USD Million)
  • Table 12.95 Antisense Oligonucleotide Market in Spain, Till 2035 (USD Million)
  • Table 12.96 Antisense Oligonucleotide Market in Australia, Till 2035 (USD Million)
  • Table 12.97 Antisense Oligonucleotide Market in Japan, Till 2035 (USD Million)
  • Table 12.98 Antisense Oligonucleotide Market in Korea, Till 2035 (USD Million)
  • Table 12.99 Antisense Oligonucleotide Market in Brazil, Till 2035 (USD Million)
  • Table 12.100 Antisense Oligonucleotide Market in Israel, Till 2035 (USD Million)
  • Table 12.101 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
  • Table 12.102 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
  • Table 12.103 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
  • Table 12.104 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
  • Table 12.105 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method Used
  • Table 12.106 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
  • Table 12.107 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
  • Table 12.108 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
  • Table 12.109 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters
  • Table 12.110 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method Used

List of Figures

  • Figure 3.1 Classification of Oligonucleotides
  • Figure 3.2 Key Components of RNA interference
  • Figure 3.3 Mechanism of RNA interference
  • Figure 3.4 Key Features of Antisense Oligonucleotides
  • Figure 3.5 Mechanism of Antisense Oligonucleotides
  • Figure 4.1 Antisense Oligonucleotide Therapeutics: Distribution by Type of Antisense Molecule
  • Figure 4.2 Antisense Oligonucleotide Therapeutics: Distribution by ASO Generation
  • Figure 4.3 Antisense Oligonucleotide Therapeutics: Distribution by Phase of Development
  • Figure 4.4 Antisense Oligonucleotide Therapeutics: Distribution by Target Genes
  • Figure 4.5 Antisense Oligonucleotide Therapeutics: Distribution by Target Indications
  • Figure 4.6 Antisense Oligonucleotide Therapeutics: Distribution by Therapeutic Areas
  • Figure 4.7 Antisense Oligonucleotide Therapeutics: Distribution by Route of Administration
  • Figure 4.8 Antisense Oligonucleotide Therapeutics: Distribution by Type of Therapy
  • Figure 4.9 Antisense Oligonucleotide Therapeutic Developers: Distribution by Year of Establishment
  • Figure 4.10 Antisense Oligonucleotide Therapeutic Developers: Distribution by Company Size
  • Figure 4.11 Antisense Oligonucleotide Therapeutic Developers: Distribution by Location of Headquarters
  • Figure 4.12 Grid Analysis: Distribution by Phase of Development of Therapeutics, Company Size and Location of Headquarters
  • Figure 5.1 Biogen: Annual Revenues, Since 2015 (USD Million)
  • Figure 5.2 Ionis Pharmaceuticals: Annual Revenues, Since 2015 (USD Million)
  • Figure 5.3 Sarepta Therapeutics: Annual Revenues, Since 2015 (USD Million)
  • Figure 5.4 Wave Life Sciences: Annual Revenues, Since 2015 (USD Million)
  • Figure 6.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
  • Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Figure 6.5 Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 6.7 Leading Players: Distribution by Number of Registered Trials
  • Figure 6.8 Word Cloud: Key Focus Areas
  • Figure 6.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Figure 6.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
  • Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
  • Figure 6.12 Popular Interventions: Distribution by Number of Registered Trials
  • Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 6.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2017
  • Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), Since 2017
  • Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 7.4 Grant Analysis: Distribution by Support Period
  • Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 7.8 Grant Analysis: Distribution by Activity Code
  • Figure 7.9 Grant Analysis: Distribution by Study Section Involved
  • Figure 7.10 Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 7.11 Word Cloud Analysis: Emerging Focus Areas
  • Figure 7.12 Grant Analysis: Geographical Distribution of Recipient Organizations
  • Figure 7.13 Popular Therapeutic Areas: Distribution by Number of Grants
  • Figure 7.14 Popular NIH Departments: Distribution by Number of Grants
  • Figure 7.15 Prominent Program Officers: Distribution by Number of Grants
  • Figure 7.16 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Antisense Molecule Involved
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Target Therapeutic Area
  • Figure 8.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 8.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 8.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.8 Partnerships and Collaborations: Regional Distribution
  • Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Global Antisense Oligonucleotide Therapeutics Market, Till 2035 (USD Million)
  • Figure 9.2 Alicaforsen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.3 Eteplirsen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.4 Golodirsen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.5 Inotersen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.6 Sepofarsen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.7 Tofersen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.8 Tominersen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.9 Viltolarsen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.10 Volanesorsen: Sales Forecast, Till 2035 (USD Million)
  • Figure 9.11 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Antisense Molecule (USD Million)
  • Figure 9.12 Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, Till 2035 (USD Million)
  • Figure 9.13 Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, Till 2035 (USD Million)
  • Figure 9.14 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by ASO Generation (USD Million)
  • Figure 9.15 Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, Till 2035 (USD Million)
  • Figure 9.16 Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, Till 2035 (USD Million)
  • Figure 9.17 Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, Till 2035 (USD Million)
  • Figure 9.18 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Target Disease Indication (USD Million)
  • Figure 9.19 Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, Till 2035 (USD Million)
  • Figure 9.20 Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, Till 2035 (USD Million)
  • Figure 9.21 Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, Till 2035 (USD Million)
  • Figure 9.22 Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, Till 2035 (USD Million)
  • Figure 9.23 Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, Till 2035 (USD Million)
  • Figure 9.24 Global Antisense Oligonucleotide Therapeutics Market for Huntington's Disease, Till 2035 (USD Million)
  • Figure 9.25 Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, Till 2035 (USD Million)
  • Figure 9.26 Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, Till 2035 (USD Million)
  • Figure 9.27 Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, Till 2035 (USD Million)
  • Figure 9.28 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Route of Administration (USD Million)
  • Figure 9.29 Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, Till 2035 (USD Million)
  • Figure 9.30 Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, Till 2035 (USD Million)
  • Figure 9.31 Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, Till 2035 (USD Million)
  • Figure 9.32 Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, Till 2035 (USD Million)
  • Figure 9.33 Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, Till 2035 (USD Million)
  • Figure 9.34 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Therapy (USD Million)
  • Figure 9.35 Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies Till 2035 (USD Million)
  • Figure 9.36 Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, Till 2035 (USD Million)
  • Figure 9.37 Global Antisense Oligonucleotide Market, Till 2035: Distribution by Geography (USD Million)
  • Figure 9.38 Antisense Oligonucleotide Market in the US, Till 2035 (USD Million)
  • Figure 9.39 Antisense Oligonucleotide Market in Canada, Till 2035 (USD Million)
  • Figure 9.40 Antisense Oligonucleotide Market in the UK, Till 2035 (USD Million)
  • Figure 9.41 Antisense Oligonucleotide Market in Germany, Till 2035 (USD Million)
  • Figure 9.42 Antisense Oligonucleotide Market in France, Till 2035 (USD Million)
  • Figure 9.43 Antisense Oligonucleotide Market in Italy, Till 2035 (USD Million)
  • Figure 9.44 Antisense Oligonucleotide Market in Spain, Till 2035 (USD Million)
  • Figure 9.45 Antisense Oligonucleotide Market in Australia, Till 2035 (USD Million)
  • Figure 9.46 Antisense Oligonucleotide Market in Japan, Till 2035 (USD Million)
  • Figure 9.47 Antisense Oligonucleotide Market in Korea, Till 2035 (USD Million)
  • Figure 9.48 Antisense Oligonucleotide Market in Brazil, Till 2035 (USD Million)
  • Figure 9.49 Antisense Oligonucleotide Market in Israel, Till 2035 (USD Million)
  • Figure 10.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
  • Figure 10.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
  • Figure 10.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
  • Figure 10.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
  • Figure 10.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method Used
  • Figure 10.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
  • Figure 10.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
  • Figure 10.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
  • Figure 10.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters
  • Figure 10.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method Used